Tiziana Fully Enrolls its Phase 2 Placebo Controlled Multiple Sclerosis Trial
Tiziana Life Sciences has fully enrolled 48 patients in its randomized, double-blind, placebo-controlled Phase 2a trial (INFORM-MS) evaluating intranasal foralumab for non-active Secondary Progressive Multiple Sclerosis (na-SPMS). The trial is the first placebo-controlled study of this novel anti-CD3 monoclonal antibody in this indication. Topline …